Lowered Rilpivirine Exposure During the Third Trimester of Pregnancy in Human Immunodeficiency Virus Type 1

Lowered Rilpivirine Exposure During the Third Trimester of Pregnancy in Human Immunodeficiency Virus Type 1–Infected Women

Published:2017-06-08 Issue:8 Volume:65 Page:1335-1341
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Schalkwijk Stein¹,Colbers Angela¹,Konopnicki Deborah²,Gingelmaier Andrea³,Lambert John⁴,van der Ende Marchina⁵,Moltó José⁶,Burger David¹,Rijnders B,van der Ven A J A M,Nicastri E,Giaquinto C,Weizsäcker K,Alba I,Kost B,Lyons F,Lambert J,Wyen C,Faetkenheuer G,Rockstroh J K,Schwarze-Zander C,Tariq Sadiq S,Gilleece Y,Wood C,Taylor G,Hawkins D,Hidalgo C,Haberl A,Fox J,van Kasteren M E E,Konopnicki D,Gingelmaier A,van der Ende M E,Moltó J,

Affiliation:

1. Radboud University Medical Center, Radboud Institute for Health Sciences, Department of Pharmacy, Nijmegen, The Netherlands;

2. Saint-Pierre University Hospital, Brussels, Belgium;

3. Klinikum der Universität München, Frauenklinik Innenstadt, Munich, Germany;

4. Mater Misericordiae University Hospital, Dublin, Ireland;

5. Erasmus Medical Center, Rotterdam, The Netherlands; and

6. Fundació Lluita contra la Sida, HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain

Funder

European Commission

Bristol-Myers Squibb

ViiV Healthcare

Merck Sharp & Dohme